Drug Search Results
More Filters [+]

BGC-515

Alternative Names: BGC-515, BGC 515, BGC515
Latest Update: 2024-06-11
Latest Update Note: Clinical Trial Update

Product Description

Discovered through our unique chemoproteomic platform, IMTAC™, the TEAD inhibitor BGC515 represents a significant breakthrough. The FDA's endorsement of this IND not only validates our innovative platform but also highlights a critical step forward in our mission to develop pioneering treatments for cancer patients. (Sourced from: https://www.bridgenebio.com/news/bridgene-biosciences-announces-fda-acceptance-of-ind-application-of-novel-tead-inhibitor-bgc515)

Mechanisms of Action: TEAD Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: BridGene Biosciences Inc.
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BGC-515

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Epithelioid Hemangioendothelioma|Mesothelioma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BGC515-101

P1

Recruiting

Epithelioid Hemangioendothelioma|Mesothelioma

2027-06-01

Recent News Events

Date

Type

Title